Comparison of collapsing methods for the statistical analysis of rare variants by Dering, Carmen et al.
PROCEEDINGS Open Access
Comparison of collapsing methods for the
statistical analysis of rare variants
Carmen Dering, Andreas Ziegler, Inke R König, Claudia Hemmelmann
*
From Genetic Analysis Workshop 17
Boston, MA, USA. 13-16 October 2010
Abstract
Novel technologies allow sequencing of whole genomes and are considered as an emerging approach for the
identification of rare disease-associated variants. Recent studies have shown that multiple rare variants can explain a
particular proportion of the genetic basis for disease. Following this assumption, we compare five collapsing approaches
to test for groupwise association with disease status, using simulated data provided by Genetic Analysis Workshop 17
(GAW17). Variants are collapsed in different scenarios per gene according to different minor allele frequency (MAF)
thresholds and their functionality. For comparing the different approaches, we consider the family-wise error rate and the
power. Most of the methods could maintain the nominal type I error levels well for small MAF thresholds, but the power
was generally low. Although the methods considered in this report are common approaches for analyzing rare variants,
they performed poorly with respect to the simulated disease phenotype in the GAW17 data set.
Background
New technologies allow the sequencing of genomes of a
large number of individuals, thus identifying millions of
rare variants in the genome. This allows researchers to
investigate the common disease/rare variants (CDRV)
hypothesis. Because these variants are rare or are even pri-
vate mutations, standard statistical approaches fail. How-
ever, different variants within a gene may act similarly.
Therefore one approach of making data accessible to sta-
tistical analysis is pooling rare variants in a specific genetic
region of interest [1]. Another advantage of this collapsing
approach is that investigations can be focused on causal
relations between genes and the phenotype of interest.
In this study we focus on the CDRV hypothesis by
grouping multiple rare variants according to a gene. To
test for groupwise association with the simulated disease
status in unrelated individuals, we compare the following
five collapsing approaches: cohort allelic sum test (CAST)
[2], combined multivariate and collapsing (CMC) method
[3], weighted-sum (WS) statistic [4], and two rare variant
tests (RVT1, the test with proportion coding; and RVT2,
the test with indicator coding) [5]. To this end, we use the
simulated data provided by Genetic Analysis Workshop 17
(GAW17).
Methods
The five different collapsing approaches have been
described in detail elsewhere, for example, by Dering et al.
[1]. Here, we briefly describe t h es p e c i f i cc o n f i g u r a t i o n s
used in our study.
For CAST we use the Fisher two-sided exact test for sta-
tistical analysis, as suggested in the original publication
[4]. For the CMC method, we use the Fisher product
method as the multivariate test.
The WS statistic was proposed by Madsen and Brown-
ing [4]. In the WS approach, p-values are obtained by per-
mutation. The classical permutation approach estimates
the proportion of permuted test statistics that exceeds the
original test statistic. If p-values are supposed to be low, a
large number of permutations is required, and this
requires a lengthy computing time. Therefore Madsen and
Browning proposed to estimate the first two moments of
the permutation distribution under the null hypothesis of
no association in the first step. In the second step, the esti-
mated mean and standard deviation from the permutation
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dize the original test statistic. This standardized test statis-
tic is finally used to estimate the p-value from the
standard normal distribution; for details, see Dering et al.
[1] and Madsen and Browning [4]. Here, we fix the num-
ber of permutations to 1,000, as suggested by Madsen and
Browning [4].
General data information
The GAW17 sequence data are based on the 1000 Gen-
omes Project [6], and phenotypes were simulated by the
GAW17 team [7]. We consider the collection of 697 unre-
lated individuals with a simulated disease phenotype. The
simulated affection status for a common disease (fre-
quency of 30%) was provided for all 200 replicates of the
phenotype and 24,487 single-nucleotide polymorphisms
(SNPs) in 3,205 genes, all of which were autosomal. Allele
frequencies for the markers range from private variants to
minor allele frequencies (MAFs) greater than 0.4, with
most variants being rare (more than 50% had MAF < 0.01,
and only 10% had MAF > 0.05).
Data preprocessing
To compare the different collapsing approaches, we con-
sider the binary disease phenotype without any covariates.
We first convert the genotype files of the GAW17 data
using PLINK, version 1.05 [8,9], to generate additive SNP
coding. For our analyses we implement CAST [2], the
CMC method [3], and the WS method [4] in R, version
2.12.0 [10]. The input data are further converted with
GTOOL, version 0.5.0 [11], into the SNPTEST format for
running GRANVIL, version 0.4, which is an implementa-
tion of RVT1 [12], and for running CCRaVAT [13], an
implementation of RVT2 [5]. GRANVIL and CCRaVAT
are run with default values.
Only genes with at least two variants are included.
Furthermore, we exclude the 695 spuriously associated
genes that were identified by Luedtke et al. [14].
We investigate three groups of variants: (1) all variants,
(2) synonymous variants only, and (3) nonsynonymous
variants only. Because the effect size of variants may
depend on their frequency, we consider different MAF
limits for collapsing: 0.01, 0.02, 0.03, 0.05, 0.07, and 0.10.
For example, for synonymous variants with MAF < 0.01,
only 4,218 variants in 765 genes with at least 2 variants
remained.
For the CMC method in all scenarios we collapse var-
iants with MAF < 0.01, and variants with larger MAFs
were investigated separately for each gene. As a conse-
quence, in scenarios with MAF < 0.01, the CMC
method and CAST were identical.
For controlling the family-wise error rate (FWER),
which is the probability of committing at least one type I
error, we set the multiple significance level to 0.05. The
local significance levels are obtained by Bonferroni cor-
rection, that is, by dividing the multiple level by the num-
ber of genes in the individual scenarios under the
assumption of independent genes. In the previous exam-
ple with synonymous variants and MAF < 0.01, the local
significance level is therefore 0.05/765 ≈ 6.5 × 10
−5.
We use two different definitions of power, namely,
average and minimal power, to compare the perfor-
mance of the different collapsing methods. The average
power is defined as the expected proportion of identified
true gene disease associations among all true associa-
tions, and the minimal power is defined as the probabil-
ity to detect at least one of the true associations. The
FWER and the power are averaged by the number of
replicates.
Results
Type I error
None of the considered collapsing methods satisfied the
multiple significance level in all scenarios (Figure 1).
Without restriction to SNP type, almost none of the
methods kept the multiple significance level, except
RVT1, the CMC method, and CAST for small MAF lim-
its (Figure 1a). When considering only synonymous
SNPs, the FWER was generally smaller, and for small
MAF thresholds RVT1, RVT2, CAST, and the CMC
method satisfied the multiple significance level (Figure
1b). For nonsynonymous SNPs only, the FWER was in
between the FWER of the other two cases (results not
shown).
Power
The minimal power for all methods was low in all sce-
narios (Table 1), and it ranged from 0% to 28.5%. The
minimal power of all methods was 0 for almost all MAF
limits when the analysis was restricted to synonymous
SNPs. In most of the considered cases, the minimal
powers of RVT2, CAST, and the CMC method were
identical. The average power was close to 0 for all meth-
ods in all scenarios (range, 0–1.2%; results not shown).
Discussion and conclusions
In this study, we focused on the CDRV hypothesis by
grouping multiple rare variants according to genes. We
compared collapsing approaches proposed in the litera-
ture using the GAW17 data of unrelated individuals.
Results differed substantially with respect to SNP
functionality. Specifically, for nonsynonymous variants
the minimal power was up to 28.5%. In contrast, the
minimal power was close to 0 for all methods in almost
every scenario when only synonymous variants were
considered. However, this result is not surprising
because no synonymous variants are directly associated
with the simulated disease phenotype.
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fered for several MAF thresholds (Table 1). Price et al.
[15] proposed an alternative method to overcome the
problem of selecting a MAF threshold. They calculated
the maximum test statistic over all reasonable MAF
thresholds. An interesting approach could therefore be a
combination of the maximum test statistic of Price et al.
[15] with the different collapsing methods.
Considering only valid methods (i.e., test statistics with
FWER ≤ 0.05), the WS approach could not be applied.
Furthermore, the remaining methods could be applied
only in the scenarios with MAF thresholds smaller than
0.05 with respect to the FWER. If both type I error and
power are considered simultaneously, we have to conclude
that none of the methods perform sufficiently well on the
simulated data.
In conclusion, none of the investigated approaches can
be recommended with respect to the simulated disease
phenotype. An improvement in the performance of the
methods could be achieved if the underlying disease
model was known. Furthermore, the inclusion of prior
knowledge, such as pathway information, or putative
functional information of the variant might be beneficial
for the analysis of real data sets.
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Figure 1 FWER for five collapsing approaches. Family-wise error rate (FWER) of all five collapsing approaches depending on different minor
allele frequency (MAF) thresholds (a) without restriction to SNP type and (b) with restriction to synonymous SNPs.
Table 1 Minimal power of five collapsing approaches
SNP type MAF WS CMC CAST RVT1 RVT2
All 0.01 0.015 – 0.010 0.010 0.010
0.02 0.025 0.030 0.030 0.040 0.030
0.03 0.070 0.050 0.050 0.060 0.055
0.05 0.035 0.050 0.050 0.060 0.050
0.07 0.120 0.115 0.115 0.125 0.115
0.10 0.135 0.075 0.075 0.115 0.070
Synonymous 0.01 0 – 000
0.02 0.005 0 0 0 0
0.03 0.005 0 0 0 0
0.05 0 0 0 0 0
0.07 0.005 0.005 0.005 0 0.005
0.10 0 0 0 0 0
Nonsynonymous 0.01 0.010 – 0.010 0 0.010
0.02 0.050 0.045 0.045 0.025 0.045
0.03 0.135 0.120 0.120 0.090 0.120
0.05 0.130 0.120 0.120 0.090 0.120
0.07 0.285 0.170 0.170 0.285 0.170
0.10 0.235 0.170 0.170 0.285 0.170
Minimal power of all five collapsing approaches for different SNP types and
MAF thresholds to control a family-wise error rate ≤ 0.05. WS, weighted-sum
method; CMC, combined multivariate and collapsing method; CAST, cohort
allelic sum test; RVT1, rare variant test with proportion coding; RVT2, rare
variant test with indicator coding.
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